North America Biologics Market Size & Outlook, 2026-2033
Global Market
Related Markets
North America biologics market highlights
- The North America biologics market generated a revenue of USD 277,877.9 million in 2025.
- The market is expected to grow at a CAGR of 9.7% from 2026 to 2033.
- In terms of segment, microbial was the largest revenue generating source in 2025.
- Mammalian is the most lucrative source segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 277,877.9 million |
| Market revenue in 2033 | USD 585,457.6 million |
| Growth rate | 9.7% (CAGR from 2026 to 2033) |
| Largest segment | Microbial |
| Fastest growing segment | Mammalian |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Microbial, Mammalian |
| Key market players worldwide | Samsung BioLogics, Amgen Inc, Novo Nordisk A/S ADR, AbbVie Inc, Sanofi SA, Johnson & Johnson, Celltrion Healthcare, Bristol-Myers Squibb Co, Eli Lilly and Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, North America region accounted for 44.4% of the global biologics market in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 310,813.4 million by 2033.
North America market of biologics accounted for the largest share as a consequence of presence of substantial players in the region that are involved in biologics development and distribution. State laws and other laws for biologics acting in the region are expected to significantly impact the progress of this market.
The presence of a large number of FDA and other regulatory agencies approved drugs for commercial use in North American countries is expected to boost revenue generation in this region. For instance, in January 2016, Health Canada granted approval to Janssen Inc.’s STELARA (ustekinumab) for the treatment of plaque psoriasis.
This is the first approved biologic in North America for the treatment of this condition. Interventions and conferences conducted in the region for pertinent technologies and issues in biologics applications for the treatment of various chronic conditions are expected to accelerate the progress of the biologic market.
No credit card required*
Publish Date: Jun 11, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Biologics Market Scope
Biologics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Johnson & Johnson | View profile | 134,400 | One Johnson and Johnson Plaza, New Brunswick, NJ, United States, 08933 | www.jnj.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Sanofi SA | View profile | 87,994 | 46, avenue de la Grande Armée, Paris, France, 75017 | www.sanofi.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Eli Lilly and Co | View profile | 43,000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | www.lilly.com |
| Novo Nordisk A/S ADR | View profile | 66,015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | www.novonordisk.com |
| Samsung BioLogics | View profile | 1001-5000 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.samsungbiologics.com/ |
| Celltrion Healthcare | View profile | 51-100 | Incheon, Inch'on-jikhalsi, South Korea, Asia | www.celltrionhealthcare.com/ |
North America Biologics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Biologics Market Outlook will help companies and investors design strategic landscapes.
Microbial was the largest segment with a revenue share of 64.03% in 2025.
Horizon Databook has segmented the North America biologics market based on microbial, mammalian covering the revenue growth of each sub-segment from 2021 to 2033.
North America market of biologics accounted for the largest share as a consequence of presence of substantial players in the region that are involved in biologics development and distribution. State laws and other laws for biologics acting in the region are expected to significantly impact the progress of this market.
The presence of a large number of FDA and other regulatory agencies approved drugs for commercial use in North American countries is expected to boost revenue generation in this region. For instance, in January 2016, Health Canada granted approval to Janssen Inc.’s STELARA (ustekinumab) for the treatment of plaque psoriasis.
This is the first approved biologic in North America for the treatment of this condition. Interventions and conferences conducted in the region for pertinent technologies and issues in biologics applications for the treatment of various chronic conditions are expected to accelerate the progress of the biologic market.
- North America Biologics Market Source Outlook (Revenue, USD Million , 2021-2033)
- Microbial
- Mammalian
- Others
- North America Biologics Market Product Outlook (Revenue, USD Million , 2021-2033)
- Monoclonal antibodies (MABs)
- Vaccines
- Recombinant Proteins
- Antisense & RNAi Therapeutics
- Others
- North America Biologics Market Disease Category Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Immunological Disorders
- Cardiovascular Disorders
- Haematological Disorders
- Others
- North America Biologics Market Manufacturing Outlook (Revenue, USD Million , 2021-2033)
- In-house
- Outsourced
Reasons to subscribe to Biologics Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Biologics Market Outlook databook
- Our clientele includes a mix of Biologics Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Biologics Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Biologics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Biologics Market, 2021-2033 (US$M)
North America Source - Biologics Market Statistics, 2025 - 2033 (US$M)
Related industry reports
No Records
No related reports found.
Related statistics
No Records
No related statistics found.